aXichem AB Cash Flow Conversion Efficiency
aXichem AB cash flow conversion efficiency. Based on the latest financial reports, aXichem AB (AXIC-A) has a cash flow conversion efficiency ratio of -0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.98 Million ≈ $-213.40K USD) by net assets (Skr58.07 Million ≈ $6.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of aXichem AB (2008–2024)
Cash flow conversion efficiency of aXichem AB from 2008 to 2024. This chart illustrates how aXichem AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AXIC-A stock price for real-time trading data and today's change.
aXichem AB Cash Flow Conversion Ratio Explained
aXichem AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
aXichem AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of aXichem AB ranked by their cash flow conversion efficiency. Also see market value of aXichem AB for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chuan Huat Resources Bhd
KLSE:7016
|
-0.039x |
|
Pure Resources Ltd
AU:PR1
|
-0.184x |
|
Schroder Oriental Income Fund
LSE:SOI
|
0.126x |
|
InnoTherapy Inc
KQ:246960
|
-0.004x |
|
Kingfish Company Nv
OL:KING
|
-0.078x |
|
Netlinkz Ltd
AU:NET
|
0.084x |
|
Active Biotech AB
ST:ACTI
|
-0.242x |
|
NPK Co.Ltd
KQ:048830
|
0.058x |
Annual Cash Flow Conversion Efficiency for aXichem AB (2008–2024)
The table below shows the annual cash flow conversion efficiency of aXichem AB from 2008 to 2024. Review aXichem AB free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr70.16 Million ≈ $7.55 Million |
Skr-11.50 Million ≈ $-1.24 Million |
-0.164x | +49.25% |
| 2023-12-31 | Skr48.53 Million ≈ $5.22 Million |
Skr-15.68 Million ≈ $-1.69 Million |
-0.323x | +31.78% |
| 2022-12-31 | Skr40.33 Million ≈ $4.34 Million |
Skr-19.10 Million ≈ $-2.06 Million |
-0.474x | -70.97% |
| 2021-12-31 | Skr56.30 Million ≈ $6.06 Million |
Skr-15.60 Million ≈ $-1.68 Million |
-0.277x | -27.08% |
| 2020-12-31 | Skr53.65 Million ≈ $5.77 Million |
Skr-11.69 Million ≈ $-1.26 Million |
-0.218x | -19.06% |
| 2019-12-31 | Skr67.15 Million ≈ $7.23 Million |
Skr-12.29 Million ≈ $-1.32 Million |
-0.183x | +28.60% |
| 2018-12-31 | Skr29.10 Million ≈ $3.13 Million |
Skr-7.46 Million ≈ $-802.92K |
-0.256x | -12.93% |
| 2017-12-31 | Skr33.86 Million ≈ $3.64 Million |
Skr-7.69 Million ≈ $-827.35K |
-0.227x | -69.82% |
| 2016-12-31 | Skr41.33 Million ≈ $4.45 Million |
Skr-5.53 Million ≈ $-594.69K |
-0.134x | +55.97% |
| 2015-12-31 | Skr26.27 Million ≈ $2.83 Million |
Skr-7.98 Million ≈ $-858.45K |
-0.304x | +36.22% |
| 2014-12-31 | Skr18.93 Million ≈ $2.04 Million |
Skr-9.01 Million ≈ $-970.05K |
-0.476x | -176.29% |
| 2013-12-31 | Skr24.92 Million ≈ $2.68 Million |
Skr-4.29 Million ≈ $-462.10K |
-0.172x | +71.74% |
| 2012-12-31 | Skr8.01 Million ≈ $862.30K |
Skr-4.89 Million ≈ $-525.79K |
-0.610x | -1199.16% |
| 2011-12-31 | Skr9.13 Million ≈ $982.51K |
Skr-428.50K ≈ $-46.11K |
-0.047x | +86.41% |
| 2010-12-31 | Skr3.28 Million ≈ $352.46K |
Skr-1.13 Million ≈ $-121.77K |
-0.345x | +34.91% |
| 2009-12-31 | Skr5.65 Million ≈ $607.93K |
Skr-3.00 Million ≈ $-322.68K |
-0.531x | -152.73% |
| 2008-12-31 | Skr7.37 Million ≈ $792.98K |
Skr7.42 Million ≈ $798.20K |
1.007x | -- |
About aXichem AB
aXichem AB, a biotechnology company, engages in the development of natural analogue ingredients in Sweden. It offers aXivite, a natural analogue capsaicin solution for a range of dietary health applications; aXiphen-bio, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings a… Read more